FT-Raman data analyzed by multivariate and machine learning as a new methods for detection spectroscopy marker of platinum-resistant women suffering from ovarian cancer.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
26 Nov 2023
26 Nov 2023
Historique:
received:
04
10
2023
accepted:
22
11
2023
medline:
28
11
2023
pubmed:
27
11
2023
entrez:
26
11
2023
Statut:
epublish
Résumé
The phenomenon of platinum resistance is a very serious problem in the treatment of ovarian cancer. Unfortunately, no molecular, genetic marker that could be used in assigning women suffering from ovarian cancer to the platinum-resistant or platinum-sensitive group has been discovered so far. Therefore, in this study, for the first time, we used FT-Raman spectroscopy to determine chemical differences and chemical markers presented in serum, which could be used to differentiate platinum-resistant and platinum-sensitive women. The result obtained showed that in the serum collected from platinum-resistant women, a significant increase of chemical compounds was observed in comparison with the serum collected from platinum-sensitive woman. Moreover, a decrease in the ratio between amides vibrations and shifts of peaks, respectively, corresponding to C-C/C-N stretching vibrations from proteins, amide III, amide II, C = O and CH lipids vibrations suggested that in these compounds, structural changes occurred. The Principal Component Analysis (PCA) showed that using FT-Raman range, where the above-mentioned functional groups were present, it was possible to differentiate the serum collected from both analyzed groups. Moreover, C5.0 decision tree clearly showed that Raman shifts at 1224 cm
Identifiants
pubmed: 38008780
doi: 10.1038/s41598-023-48169-3
pii: 10.1038/s41598-023-48169-3
pmc: PMC10679116
doi:
Substances chimiques
Platinum
49DFR088MY
Proteins
0
Amides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20772Informations de copyright
© 2023. The Author(s).
Références
Ann Oncol. 2019 May 1;30(5):672-705
pubmed: 31046081
Molecules. 2023 Jun 06;28(12):
pubmed: 37375138
Curr Oncol Rep. 2020 Jun 4;22(6):64
pubmed: 32494876
Int J Cancer. 2021 Apr 5;:
pubmed: 33818764
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Geburtshilfe Frauenheilkd. 2021 Oct;81(10):1145-1153
pubmed: 34629493
Nat Commun. 2018 Jul 26;9(1):2923
pubmed: 30050129
Int J Cancer. 2003 Dec 20;107(6):1047-52
pubmed: 14601068
Exp Biol Med (Maywood). 2018 Apr;243(7):655-662
pubmed: 29466876
Int J Gynecol Cancer. 2011 May;21(4):750-5
pubmed: 21543936
Semin Cancer Biol. 2017 Jun;44:67-71
pubmed: 28450177
J R Soc Interface. 2004 Nov 22;1(1):79-90
pubmed: 16849154
Br J Cancer. 2022 May;126(8):1125-1139
pubmed: 34893761
Br J Cancer. 2006 Feb 13;94(3):436-45
pubmed: 16421595
Front Pharmacol. 2020 Mar 20;11:343
pubmed: 32265714
Photomed Laser Surg. 2013 Dec;31(12):595-604
pubmed: 24251927
Br J Cancer. 2006 May 22;94(10):1460-4
pubmed: 16622450
Gynecol Oncol. 2014 Jun;133(3):624-31
pubmed: 24607285
J Ovarian Res. 2009 Apr 14;2:4
pubmed: 19366455
Endocr Relat Cancer. 2018 May;25(5):R303-R318
pubmed: 29487129
Cancer Res. 2020 Apr 15;80(8):1748-1761
pubmed: 32054768
Int J Gynecol Cancer. 2011 May;21(4):771-5
pubmed: 21543939
Biopolymers. 2006 Feb 15;81(3):179-93
pubmed: 16231284
Eur J Pharmacol. 2014 Oct 5;740:364-78
pubmed: 25058905